Skip to content

US · SCNI · BIOTECHNOLOGY

Scinai Immunotherapeutics Ltd. (SCNI) intrinsic value and stock valuation

$1.58as of 2026-11-21 · Mkt cap 328.84K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Scinai Immunotherapeutics Ltd. DCF and intrinsic value

InvestorsCraft values SCNI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SCNI’s statements →

Scinai Immunotherapeutics Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Jerusalem, JM 9112001 scinai.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.31M
20112025
Net income
-$-8.31M
20112025
Free cash flow
-$-6.05M
20112025
Total equity
$8.1M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.31M$660K$0.00$0.00$0.00
Operating income-$-7.54M-$-8.64M-$-9.71M-$-11.06M-$-10.87M
Net income-$-8.31M$4.8M-$-6.5M-$-5.8M-$-8.21M
EPSd-$-3.57M$5.93M-$-16.67M-$-30.53M-$-58.64M
Operating cash flow-$-6.03M-$-6.33M-$-9.38M-$-7.26M-$-7.43M
Capital expenditure-$-20K-$-10K-$-640K-$-840K-$-130K
Free cash flow-$-6.05M-$-6.35M-$-10.02M-$-8.1M-$-7.57M
Total assets$11.6M$13.5M$17.5M$27.1M$32M
Total debt$2.27M$2.09M$20.6M$21.5M$29.2M
Net debt$610K$120K$15.7M$7.47M$11.9M
Total equity$8.1M$9.98M-$-4.57M-$-1.76M$980K
Cash and short-term investments$1.66M$1.96M$4.87M$14.1M$17.4M
Income statement
20252024202320222021
Revenue$1.31M$660K$0.00$0.00$0.00
Cost of revenue$3.96M$1.24M$510K$560K$750K
Gross profit-$-2.65M-$-580K-$-510K-$-560K-$-750K
Research and development expenses$2.37M$5.53M$5.21M$5.76M$3.25M
Selling, general and administrative expenses$2.52M$2.53M$4.5M$5.3M$7.62M
Other expenses$0.00$0.00-$-10K$0.00-$-10K
Operating expenses$4.89M$8.06M$9.71M$11.1M$10.9M
Cost and expenses$8.85M$9.3M$9.71M$11.1M$10.9M
Interest income$20K$100K$120K$8.1M$0.00
Interest expense$360K$1.44M$10K$5.05M$3.36M
Depreciation and amortization$1.42M$1.65M$510K$560K$470K
Ebitda-$-6.53M-$-6.99M-$-9.19M-$-10.5M-$-10.39M
Operating income-$-7.54M-$-8.64M-$-9.71M-$-11.06M-$-10.87M
Total other income/expenses, net-$-770K$13.4M$3.21M$5.26M$2.67M
Income before tax-$-8.31M$4.8M-$-6.5M-$-5.8M-$-8.21M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-8.31M$4.8M-$-6.5M-$-5.8M-$-8.21M
Weighted average shares outstanding$2.33M$810K$390K$190K$100K
Weighted average diluted shares outstanding$2.33M$810K$390K$190K$140K
Balance sheet
20252024202320222021
Cash and short-term investments$1.66M$1.96M$4.87M$14.1M$17.4M
Net receivables$170K$220K$330K$0.00$330K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$2.05M$2.39M$5.45M$14.4M$17.8M
Property, plant and equipment, net$9.57M$11.1M$12M$12.7M$14.2M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$9.57M$11.1M$12M$12.7M$14.2M
Total assets$11.6M$13.5M$17.5M$27.1M$32M
Accounts payable$410K$380K$540K$720K$1M
Short-term debt$330K$420K$790K$380K$620K
Deferred revenue$90K$230K$0.00$0.00$0.00
Total current liabilities$1.58M$1.81M$1.78M$2.34M$2.44M
Long-term debt$1.94M$1.66M$20.2M$21.2M$28.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.94M$1.67M$20.3M$26.5M$28.6M
Capital lease obligations$1.97M$1.83M$1.19M$1.46M$1.82M
Total liabilities$3.52M$3.47M$22M$28.8M$31.1M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-125.85M-$-117.54M-$-122.33M-$-115.83M-$-110.04M
Accumulated other comprehensive income (loss)-$-1.74M-$-1.74M-$-1.74M-$-2.01M-$-2.06M
Total equity$8.1M$9.98M-$-4.57M-$-1.76M$980K
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$2.27M$2.09M$20.6M$21.5M$29.2M
Net debt$610K$120K$15.7M$7.47M$11.9M
Cash flow statement
20252024202320222021
Net income-$-8.31M$4.8M-$-6.5M-$-5.8M-$-8.21M
Depreciation and amortization$1.42M$1.65M$510K$560K$470K
Stock-based compensation$300K$680K$1.14M$1.6M$2.76M
Change in working capital$160K$110K-$-650K$450K$700K
Accounts receivable$50K$140K-$-290K$140K$60K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$30K-$-160K$0.00$0.00$0.00
Net cash provided by operating activities-$-6.03M-$-6.33M-$-9.38M-$-7.26M-$-7.43M
Investments in property, plant and equipment-$-20K-$-10K-$-640K-$-840K-$-140K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-20K-$-10K-$-640K-$-840K-$-140K
Common stock issued$5.77M$2M$140K$6.75M$21.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$5.77M$3.44M$1.09M$6.78M$21.4M
Net change in cash-$-280K-$-2.92M-$-9.21M-$-3.3M$14.4M
Cash at end of period$1.81M$2.1M$5.01M$14.2M$17.5M
Operating cash flow-$-6.03M-$-6.33M-$-9.38M-$-7.26M-$-7.43M
Capital expenditure-$-20K-$-10K-$-640K-$-840K-$-130K
Free cash flow-$-6.05M-$-6.35M-$-10.02M-$-8.1M-$-7.57M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Scinai Immunotherapeutics Ltd.

        Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.

        CEO
        Amir Reichman
        Employees
        45
        Beta
        2.11

        Explore

        Frequently asked questions

        What is the intrinsic value of Scinai Immunotherapeutics Ltd. (SCNI)?

        InvestorsCraft does not currently publish an intrinsic value for SCNI. How the IC value is calculated.

        Is SCNI undervalued?

        InvestorsCraft does not publish an undervaluation signal for SCNI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.